secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eikon Therapeutics, Inc. (EIKN)
CIK:        0001861123
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001193125-26-130449
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eikon Therapeutics reports Q4/FY2025 net loss $79.7M/$333.6M; IPO raised $381M
------------------------------------------------------------------------------

- Net loss attributable to common stockholders was $79.7M in Q4 2025 and $333.6M for full year 2025.
- Cash, cash equivalents and marketable securities $336M as of Dec 31, 2025; added $381.2M from IPO in Feb 2026.
- Completed enrollment of TeLuRide-005 Phase 2 trial of EIK1001 in first-line stage 4 NSCLC; data expected 2H 2026.
- R&D expenses $65.2M in Q4 2025 (+21% YoY); $250.3M for FY2025 (+22% YoY).
- Elected David W. Meline (former CFO of Moderna, Amgen, 3M) as independent director in December 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861123/000119312526130449/0001193125-26-130449-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861123/000119312526130449/d244624d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-130449

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer